🔗 Share this article

As the United States undertakes historic revisions to its vaccine schedules, an unexpected name appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by expressing skepticism about Covid vaccinations during the pandemic and has focused upon potential deaths after COVID-19 vaccination in her short position at the FDA.

Proposed Overhauls to Pediatric Vaccine Schedule

Agency leaders had intended to reveal sweeping revisions to the childhood vaccine schedule recently, bringing the US with Denmark’s immunization schedule, sources say – a major change that would place the US out of step with much of the global community with insufficient data for public health gain. The announcement has been postponed until the coming year.

In place of the director of the vaccine center, Høeg is listed to speak at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this calendar year.

Consolidating Power at the FDA

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it points to a greater focus upon reevaluating previously authorized immunizations at the FDA.

The new acting director has often pushed for halting specific pediatric immunization guidelines in the US to become more in line with the Danish model, a nation with universal health coverage and a population roughly the size of Wisconsin’s.

So far public appearances, she has continued to focus on vaccination policy – typically the responsibility of Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Questions Over Qualifications

The appointee has little discernible experience in medication creation, oversight or management, which has been standard for former directors of the biologics center. She has served at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She is not versed in leading a large organization. She lacks background in industry regulation.”

Past commissioners of CBER would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she lacks the kind of background that former directors who ran CBER have had.”

CDER has an enormous workload at the FDA, the former commissioner stated.

“Many people just zeroes in on the novel medication approvals, but the generic drug division clears thousands of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and more, and each of these have to be supervised,” Woodcock explained. “The area you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative component to the role, which oversees over 5,000 employees. “It is a massive administrative position, if you perform it correctly,” the former official concluded.

Response and Controversial Policies

When asked about concerns about Dr. Høeg's qualifications and whether this selection represents more teamwork among agency officials on vaccines, a spokesperson responded that the “inquiries stem from flawed presumptions”.

“Her resume matches the duties of her position,” the representative explained, noting the months Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg takes over the agency head's controversial expedited review system, a controversial one-day therapy clearance system that apparently troubled her former heads. “By what process are these drugs being picked for this fast-track system? Who is making the calls?” Howard said. “There’s a lot of secrecy happening at the FDA right now.”

In general, he remarked, “the agency seems to be moving towards laxer rules of pharmaceuticals, except for shots.”

Established History on Vaccines

Regarding vaccines, Høeg has a more documented, if concerning, history, Howard said. She published a study using non-validated public submissions to assess the rate of heart inflammation following Covid immunization. She advised the Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are riskier than they are.

Part of her “desired changes” for the new administration encompassed altering rules for recently developed shots and discontinuing “unnecessary” immunizations, she stated following the vote on a audio program. At the FDA, Dr. Høeg has allegedly proposed excluding young men from receiving Covid vaccines.

“She’s an all-around ideologue who commences with her preconceived notions and works backwards to retrofit the science in a very deceptive, untruthful way,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg joined other dissenters, {like|